Schwaibold H - Search Results

1

Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder.

Schwaibold H, Huland E, Heinzer H, Schwuléra U, Huland H. Schwaibold H, et al. J Cancer Res Clin Oncol. 1995;121(4):239-46. doi: 10.1007/BF01366969. J Cancer Res Clin Oncol. 1995. PMID: 7751323 Clinical Trial.

2

Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.

Huland E, Schwaibold H, Klän R, Huland H. Huland E, et al. Among authors: schwaibold h. Urology. 1995 Jan;45(1):54-7; discussion 57-8. doi: 10.1016/s0090-4295(95)96582-3. Urology. 1995. PMID: 7817481 Clinical Trial.

3

Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder.

Erbersdobler A, Friedrich MG, Schwaibold H, Henke RP, Huland H. Erbersdobler A, et al. Among authors: schwaibold h. Oncol Res. 1998;10(8):415-20. Oncol Res. 1998. PMID: 10100758

4

Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.

Friedrich MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. Friedrich MG, et al. Among authors: schwaibold h. J Urol. 2000 Mar;163(3):1039-42. J Urol. 2000. PMID: 10688045 Clinical Trial.

5

Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.

Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Friedrich MG, et al. Among authors: schwaibold h. Eur Urol. 2007 Oct;52(4):1123-29. doi: 10.1016/j.eururo.2007.02.063. Epub 2007 Mar 12. Eur Urol. 2007. PMID: 17383080 Clinical Trial.

6

[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].

Schwaibold H, Klingenberger HJ, Huland H. Schwaibold H, et al. Urologe A. 1994 Nov;33(6):479-83. Urologe A. 1994. PMID: 7817443 Clinical Trial. German.

7

Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder.

Lee E, Schwaibold H, Fradet Y, Huland E, Huland H. Lee E, et al. Among authors: schwaibold h. J Urol. 1997 Mar;157(3):1070-3. J Urol. 1997. PMID: 9072545

8

Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?

Schwaibold H, Pichlmeier U, Klingenberger HJ, Huland H. Schwaibold H, et al. Eur Urol. 1997;31(2):153-9. doi: 10.1159/000474441. Eur Urol. 1997. PMID: 9076457 Clinical Trial.

9

Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.

Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Sölter JK, Huland E, Riethdorf L, Conrad S, Hammerer PG, Huland H. Friedrich MG, et al. Among authors: schwaibold h. Eur Urol. 2001 Feb;39(2):159-66. doi: 10.1159/000052431. Eur Urol. 2001. PMID: 11223675

10

p53 in noncancerous bladder mucosa as a marker of disease recurrence in patients with superficial transitional cell carcinoma of the bladder.

Friedrich MG, Schwaibold H, Wintzer O, Pichlmeier U, Huland H. Friedrich MG, et al. Among authors: schwaibold h. Urol Oncol. 1997 Jul-Aug;3(4):125-31. doi: 10.1016/s1078-1439(98)00018-0. Urol Oncol. 1997. PMID: 21227117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters